CD8A and neoplasm: Oliveira et al. analyzed T cell activation and dynamics in responders and non-responders to neoadjuvant pembrolizumab in HNSCC patients, finding that tumors responding to pembrolizumab contained a population of tumor-infiltrating CD8+ T cells expressing genes associated with T cell exhaustion, tissue residence, and cytotoxic potential [38].